Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual)
Landos Biopharma (NASDAQ: LABP) announced that CEO Josep Bassaganya-Riera will participate in the Truist Securities CEO Fireside Chat Series on September 30, 2021. The event will feature a discussion led by Dr. Robyn Karnauskas, focusing on Landos' innovative work in developing therapeutics for autoimmune diseases using its LANCE® A.I. platform. Landos has 17 programs targeting various conditions, including ulcerative colitis and Crohn's disease, and plans to initiate Phase 1 studies in eosinophilic esophagitis in 2022.
- None.
- None.
BLACKSBURG, Va., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® advanced A.I. platform to develop novel therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will participate in the Truist Securities CEO Fireside Chat Series (Virtual). The event will feature a one-one-one conversation led by Robyn Karnauskas, Ph.D., Managing Director and Senior Biotechnology Analyst, with audience participation, discussing all aspects of Landos Biopharma. Investors interested in participating should contact their Truist Securities’ representative or, Marek Ciszewski, IR@LandosBiopharma.com.
Event: Truist Securities CEO Fireside Chat Series (Virtual)
Date: September 30, 2021
Time: 10:00 am ET – 11:00 am ET
About Landos Biopharma
Landos Biopharma is a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases. Using the LANCE® platform, the Company has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Its lead product candidate, omilancor, targets the LANCL2 pathway and is a novel oral, gut-restricted, small-molecule potentially first-in-class therapeutic currently being prepared for global pivotal Phase 3 trials for the treatment of ulcerative colitis, in two active Phase 2 trials in Crohn’s disease, and is anticipated to initiate Phase 1 studies in eosinophilic esophagitis in 2022. Omilancor is also being studied in a topical formulation for psoriasis and atopic dermatitis. Landos has another novel, oral, gut-restricted small-molecule drug candidate, NX-13, that is being investigated in an active Phase 1b trial in ulcerative colitis. NX-13 targets the NLRX1 pathway. Landos’ sixth new product candidate, LABP-104, will be entering Phase 1 clinical testing in healthy volunteers in Q4 of 2021. Additional product candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, Alzheimer’s disease, non-alcoholic steatohepatitis (NASH), asthma, chronic obstructive pulmonary disease (COPD), diabetes, and diabetic nephropathy. For more information, please visit www.landosbiopharma.com.
Contacts:
Marek Ciszewski, JD
Landos Biopharma
562-373-5787
IR@LandosBiopharma.com
Michael K. Levitan (investors)
Solebury Trout
646-378-2920
mlevitan@soleburytrout.com
Hannah Gendel (media)
Solebury Trout
646-378-2943
hgendel@soleburytrout.com
FAQ
When is the Truist Securities CEO Fireside Chat featuring LABP's CEO?
Who will lead the discussion at the LABP CEO Fireside Chat?
What is the focus of Landos Biopharma's research?
What are the current clinical trials for LABP's lead product candidate?
What is the significance of the LANCE® A.I. platform for LABP?
